We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,151

New Federal Telemedicine Grants Announced; Florida Not Listed
  • Foley & Lardner LLP
  • USA
  • September 22 2016

The U.S. Department of Agriculture just announced new grant funding awarded to seven telemedicine and 11 distance learning projects across 16 states


GMO Food Labeling And CRISPR
  • Foley & Lardner LLP
  • USA
  • September 22 2016

A new law targeted at GMO food labeling instructs the Secretary of Agriculture to establish standards for identifying “bioengineered” food. While


Inherent Disclosure Satisfied Written Description
  • Foley & Lardner LLP
  • USA
  • September 21 2016

In Yeda Research and Development Co., Ltd. v. Abbott GMBH & Co. KG, Slip Op. 2015-1662 (Fed. Cir. 2016), the Federal Circuit held that a claim to an


Personalized Medicine: Insights Into Current Legal Issues
  • Foley & Lardner LLP
  • USA
  • September 18 2016

In his January 20, 2015 State of the Union Address, President Obama brought to the nation’s attention the promise of personalized medicine when he


Apotex Biosimilar Cleared Of Infringement But Pre-Marketing Notice Still Required
  • Foley & Lardner LLP
  • USA
  • September 15 2016

In what may be the first decision on the merits in a patent infringement suit brought under the Biologics Price Competition and Innovation Act


Magistrate Judge Nixes TB Test Kit Claims
  • Foley & Lardner LLP
  • USA
  • September 13 2016

In a "Report and Recommendation on Defendants' Joint Motion To Dismiss," U.S. Magistrate Judge Cabell of the U.S. District Court for the District of


Don’t Let Zika Bug Your Employees
  • Foley & Lardner LLP
  • USA
  • September 12 2016

If you are reading this from one of the 3,141 counties in the continental United States that has not yet been affected by the Zika virus, do not turn


The EpiPen Controversy Signals Intensifying Scrutiny of Drug Classification Under Medicaid Rebate Program
  • Foley & Lardner LLP
  • USA
  • September 7 2016

Price increases threatening the availability of EpiPen and EpiPen Jr Auto-Injectors (“EpiPen”) have touched off the latest firestorm over drug


The Top 10 Things you Need to Know About Voluntary Disclosures and Government Refunds
  • Foley & Lardner LLP
  • USA
  • September 6 2016

In February 2016, CMS issued the highly anticipated Final Rule on reporting and returning Medicare Part A and B overpayments. The Final Rule was


District Court Upholds Eligibility Of Personalized Medicine Method Claims For FANAPT
  • Foley & Lardner LLP
  • USA
  • September 6 2016

In Vanda Pharmaceuticals Inc. v. Roxane Labs., Inc., Judge Stark of the U.S. District Court for the District of Delaware upheld the patent